Suven Pharma Approves Acquisition Of Casper Pharma For $20.5 Million
Suven Pharmaceuticals Ltd. will acquire Casper Pharma Pvt. for $20.5 million (Rs 155 crore).
The board of directors in its meeting on April 5 has approved the purchase of 100% share capital of the Hyderabad-based formulations manufacturing company from its existing shareholders, according to an exchange filing. That would make Casper a wholly-owned subsidiary of Suven.
The acquisition, the filing said, is expected to be completed within 30 days. No approvals are required.
Venkat Jasti, managing director at Suven, during the third-quarter earnings call had indicated that the company's legal and financial divisions are evaluating the acquisition.
Casper has an installed manufacturing capacity of 1.2 billion for solid oral dose forms such as tablets or capsules. Jasti, in the call, had said Casper plans to enter liquid manufacturing. Its facility is a 13-acre site with six abbreviated new drug applications filed.
Casper, according to the filing, is “ready for an U.S. FDA inspection, expected to happen within next six months”. Set up in January 2016, the company is yet to reach its “commercially viable operations”. No turnover details are available.
In 2019, Suven acquired Rising Pharma Holdings, which has an existing long-term contract with Casper for manufacturing and supply of products developed by Rising Pharma on a profit-sharing basis, Jasti had said on the earnings call.
Casper's acquisition, according him, is aimed at having all products that are under development at Rising Pharma R&D to be exclusively manufactured at Casper.
The arrangement with Rising Pharma indicates that the business is in line with the Suven's current pharma contract development and manufacturing business segment, which reported a revenue of around Rs 564 crore in the nine months ended December and contributed to around 60% to the company's overall revenue.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
